Identification of Serum MicroRNAs as Novel Non-Invasive Biomarkers for Early Detection of Gastric Cancer by Song, Ming-yang et al.
Identification of Serum MicroRNAs as Novel Non-Invasive
Biomarkers for Early Detection of Gastric Cancer
Ming-yang Song
1, Kai-feng Pan
1*, Hui-juan Su
1, Lian Zhang
1, Jun-ling Ma
1, Ji-you Li
2, Yasuhito Yuasa
3,
Daehee Kang
4, Yong Sung Kim
5, Wei-cheng You
1*
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital and
Institute, Beijing, People’s Republic of China, 2Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, People’s Republic of China,
3Department of Molecular Oncology, Tokyo Medical and Dental University, Tokyo, Japan, 4Department of Preventive Medicine, Seoul National University College of
Medicine, Seoul, Korea, 5Korea Research Institute of Bioscience and Biotechnology, Medical Genomics Research Center, Daejeon, Korea
Abstract
Background: To investigate the potential of serum miRNAs as biomarkers for early detection of gastric cancer (GC), a
population-based study was conducted in Linqu, a high-risk area of GC in China.
Methodology/Principal Findings: All subjects were selected from two large cohort studies. Differential miRNAs were
identified in serum pools of GC and control using TaqMan low density array, and validated in individual from 82 pairs of GC
and control, and 46 pairs of dysplasia and control by real-time quantitative reverse transcription-polymerase chain reaction.
The temporal trends of identified serum miRNA expression were further explored in a retrospective study on 58 GC patients
who had at least one pre-GC diagnosis serum sample based on the long-term follow-up population. The miRNA profiling
results demonstrated that 16 miRNAs were markedly upregulated in GC patients compared to controls. Further validation
identified a panel of three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection, and
receiver operating characteristic (ROC) curve-based risk assessment analysis revealed that this panel could distinguish GCs
from controls with 82.4% sensitivity and 58.8% specificity. MiR-221 and miR-376c demonstrated significantly positive
correlation with poor differentiation of GC, and miR-221 displayed higher level in dysplasia than in control. Furthermore, the
retrospective study revealed an increasing trend of these three miRNA levels during GC development (P for trend,0.05),
and this panel could classify serum samples collected up to 5 years ahead of clinical GC diagnosis with 79.3% overall
accuracy.
Conclusions/Significance: These data suggest that serum miR-221, miR-376c and miR-744 have strong potential as novel
non-invasive biomarkers for early detection of GC.
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Introduction
Gastric cancer (GC) is the second leading cause of cancer death
in the world, with nearly half occurring in China [1,2]. The
prognosis of GC varies remarkably by the stage of cancer with the
5-year relative survival rate reaching 90% in Stage I but less than
5% in Stage IV [3]. Thus, early detection of GC is a key measure
to reduce the mortality and improve the prognosis of GC.
Although gastroscopic screening for GC is highly reliable, it is
invasive and costly, particularly for the developing countries.
Therefore, much effort has been made to develop less expensive
preliminary screening tests in easily accessible specimens. Howev-
er, many previously investigated analytes, such as pepsinogen (PG)
I/II ratio, carcinoembryonic antigen (CEA) and carbohydrate
antigen 19-9 (CA 19-9), were not sensitive and specific enough for
GC screening [3,4]. Thus, there is an urgent need for new non-
invasive biomarkers to improve the early detection of GC.
MicroRNAs (miRNAs) are an abundant class of small non-
coding RNAs that negatively regulate gene expression by base
pairing with the 39-untranslated region of target mRNAs, resulting
in either mRNA cleavage or translational repression [5,6].
Increasing evidence has shown that miRNAs are involved in
various biological processes, including development, cell differen-
tiation, proliferation and apoptosis [7], and participate in human
carcinogenesis as oncogenes or tumor suppressors [8]. Studies
have indicated that miRNA expression profile varies among tumor
types and can differentiate cancer and normal tissues [9,10].
Recently, circulating miRNAs have been suggested great potential
as biomarkers for many cancers, including GC [11–16]. However,
the value of circulating miRNAs in early detection of GC has not
been reported yet.
Since 1989, we have conducted a series of studies in Linqu
County, a high-risk area of GC in Shandong Province, China,
including a population-based cohort study of precancerous gastric
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gastric lesions [19]. This cohort allows us to investigate the
dynamic changes in circulating miRNA levels during GC
development, and provides us a unique opportunity to explore
the potential of circulating miRNAs in early detection of GC.
Herein, we report the results of differential miRNAs in the
serum of GC and dysplasia (DYS), and a retrospective study
designed to evaluate the dynamic changes during GC develop-
ment.
Materials and Methods
Study design and population
The details of study population, procedures of endoscopic
examination, criteria of gastric histopathology and follow-up have
been described elsewhere [17–19]. Briefly, an endoscopic
screening survey was launched in 1989 among 3399 residents
aged 35–64 years in Linqu County, a high-risk area of GC, and
the subjects without GC diagnosis were subsequently followed up
with the repeated endoscopic examination conducted in 1994
[17,18]. In 1995, a randomized, placebo-controlled intervention
trial was initiated in this population until 2003, when repeated
endoscopic examination was performed [19]. All subjects
underwent blood draw in both the baseline and end-point surveys
of each study, and some with advanced gastric lesions, such as
intestinal metaplasia (IM) or DYS, also provided blood and
received endoscopic examination in 1992 and 1999.
In the current study, a multi-stage, nested case-control study
from two large cohorts was designed to identify and validate the
differential serum miRNAs in GC and DYS, and a retrospective
study was conducted to investigate the potential of candidate
serum miRNAs in early detection of GC (Figure 1).
This study was divided into four stepwise phases. In phase I,
serum pools from 14 GC patients and 14 age- and sex-matched
controls with the diagnosis of superficial gastritis (SG) or mild
chronic atrophic gastritis (CAG) were used to generate miRNA
profiles by array analysis. Differential miRNAs were identified, and
the extremely upregulated miRNAs or moderately upregulated
miRNAs having functional or biomarker-related reports were
selected for further analysis. In phase II, identified miRNAs were
validated using quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) on the individual serum samples of 14 GCs
andcontrolsthat wereused forthe arraytest inphaseI.Inphase III,
the significantly altered miRNAs were subsequently validated in 68
GC and 46 DYS patients as well as their age- and sex-matched
controls. Receiver operating characteristic (ROC) curve-based risk
assessment analysis was then performed among the 68 GC-control
pairs to evaluate the discriminating effect of serum miRNAs on GC.
Each subject was assigned into either high- or low-risk groups by
comparing the expression levels of miRNA biomarkers to the
corresponding cut-off values derived from ROC curve. In phase IV,
a retrospective study was conducted in 58 GC patients, who
provided at least one eligible pre-diagnosis serum sample in the
long-term follow-up study as described above, to explore the
temporal trend of potential miRNA biomarkersand determinetheir
value in early GC detection. The whole study was approved by the
Institutional Review Board of Peking University Cancer Hospital &
Institute, and all subjects gave written informed consent.
Figure 1. The flow chart of the study design.
doi:10.1371/journal.pone.0033608.g001
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Up to 5 ml of whole blood from each fasting participant was
collected with cases and controls done at the same year. Blood
samples were allowed to stand for 30–40 min and serum
separation was accomplished by centrifugation at 965 g for
15 min. The supernatant serum was recovered and stored at
280uC until analysis. RNA was isolated from 100 mL serum using
the miRNeasy Mini Kit (Qiagen, Germany) following the
manufacturer’s protocol with minor modification [20]. For
miRNA profiling, two pools were created by combining the
mixtures of upper aqueous phase after phase separation and
ethanol from 14 GC patients (12 male, 2 female; age, 62 (SD 6.4)
years) and 14 sex- and age-matched controls (age, 61 (SD 5.9)
years), respectively. After binding to the membrane of RNeasy
Mini spin column and subsequent washing, RNA was eluted with
40 mL of RNase-free water. For all qRT-PCR experiments, RNA
extracted from 100 ml of serum was eluted with 100 mL of RNase-
free water. To normalize the sample-to-sample variation in RNA
isolation step, synthetic ath-miR-159a was added to each serum
sample for miRNA profiling while cel-miR-39 was added for qRT-
PCR analysis as described by Mitchell et al [11].
MiRNA profiling
MiRNA profiling was performed using TaqMan low density
array A (v2.0) according to the manufacturer’s recommended
protocol (Applied Biosystems, Foster City, CA, USA). This qRT-
PCR profiling platform consists of the one 384-well microfluidic
card in which 377 miRNAs can be analysed together with three
endogenous controls (U6, RNU44 and RNU48) and one negative
control unrelated to human (ath-miR-159a). In brief, the RNA
pooled separately from 14 GC patients and matched controls as
described above was reverse transcribed using the TaqMan
miRNA reverse transcription kit and TaqMan miRNA multiplex
RT assays (human pool; Applied Biosystems). For each RNA pool,
3 ml of total RNA was added to each of the multiplex reverse
transcription reactions.
To increase the amount of cDNA available for analysis,
enrichment of target genes was performed with a preamplification
step. The 25-ml reaction mixture consisted of 2.5 ml of undiluted
cDNA combined with 12.5 ml of TaqMan PreAmp Master Mix
(26), 2.5 ml of Megaplex PreAmp Primers (106), and 7.5 mlo f
nuclease-free water. The preamplification step was performed on a
GeneAmp PCR System 9700 (Applied Biosystems) following the
manufacturer’s protocol.
For real-time PCR analysis, the product was diluted by adding
75 ml of nuclease-free water, and 9 ml of the diluted mixture was
subsequently combined with 450 ml of TaqMan 26Universal PCR
Master Mix without uracil-N-glycosylase and 441 ml of nuclease-
free water. After loading 100 ml of each multiplex pool mixture,
the array was centrifuged and sealed. Amplification was performed
on an Applied Biosystems 7900 HT thermal cycler (Applied
Biosystems) using the manufacturer’s recommended cycling
conditions. Data were analysed using RQ Manager Software
version 1.2 and DataAssist
TM Software version 2.0 (Applied
Biosystems). After normalization using the spiked-in ath-miR-
159a, the fold change of miRNAs levels in GC compared to
control was calculated by the 2-DDCt method.
MiRNA quantification by real-time qRT-PCR
Reverse transcription was performed using the TaqMan
miRNA reverse transcription kit and miRNA-specific stem-loop
primers (Applied Biosystems). The 7.5-ml reaction mixture
consisted of 0.75 mlo f1 0 6Reverse-transcription buffer, 0.095 ml
of RNase inhibitor (20 units/ml), 0.075 ml of 100 mM dNTPs with
dTTP, 0.5 ml of MultiScribe reverse-transcriptase (50 units/ml),
1.5 ml of primer, 2.5 ml of RNA, and 2.08 ml RNase-free water.
Reverse transcription was performed on a T professional PCR
System(Biometra,Germany)followingthemanufacturer’sprotocol.
Real-time PCR was performed in duplicate and included no-
template negative controls. For the 20-ml reaction, cDNA (3 ml)
was combined with 10 ml of TaqMan 26Universal PCR Master
Mix without uracil-N-glycosylase, 1 ml of the TaqMan miRNA
assay mix, and 6 ml of water. Amplification was performed on a
7500 Real-Time PCR system (Applied Biosystems) following the
manufacturer’s protocol. The expression levels of miRNAs were
normalized to the spiked-in cel-miR-39, and were calculated using
the 2-DDCt method.
Statistical analysis
The paired t test was used to examine the difference in mean
age between groups. The Wilcoxon test or Mann–Whitney U test
was used to compare the serum miRNA levels of different groups
where appropriate. ROC curves were established to evaluate the
diagnostic effects of miRNAs, and the generalized linear model
with repeated measures was employed to analyse the temporal
trends of serum miRNA levels during GC development after
logarithmic transformation. All P values were two-sided and less
than 0.05 was considered statistically significant. All statistical
analyses were performed using the Statistical Package for the
Social Sciences (SPSS 13.0, Chicago, IL).
Results
Subject characteristics
A total of 82 GC patients, 46 subjects with DYS, and 128
controls with SG or mild CAG were included in this study. As
shown in Table 1, there was no significant difference in ages
between patients with GC or DYS and their corresponding
controls (P=0.329 and 0.214, respectively).
MiRNA profiling
The differentially expressed miRNAs were identified in serum
pools of 14 GCs and 14 controls using TaqMan low density array.
Among 377 miRNAs analysed, 99 showed .2-fold upregulated
and 40 showed ,0.5-fold downregulated changes in GC serum
pool (Table S1). Sixteen upregulated miRNAs (miR-221, miR-
744, miR-376c, miR-191, miR-27a, let-7e, miR-27b, miR-222,
miR-21, miR-18a, miR-19a, miR-17, miR-106b, miR-106a, miR-
20a, and miR-155) demonstrating remarkable expression changes
in GC serum and having functional or differential expression
reports in GC tissue were selected as the candidates for the fist-
stage validation [21–28].
First-stage validation
The expressions of 16 candidate miRNAs were measured in
individual serum samples of 14 GCs and controls that were used
for array test. Consistently with the profiling results, all 16
miRNAs showed higher serum levels in GC group than in control
group (Figure S1). Among them, 9 serum miRNAs (miR-221,
miR-744, miR-376c, miR-191, miR-27a, let-7e, miR-27b, miR-
222, and miR-21) had .2 average fold change in GC group
compared to control group (P,0.05), and were thus chosen for
further validation.
Second-stage validation
We examined the 9 miRNA expressions on a large set of serum
from 68 pairs of GC and control. As shown in Figure 2, 8 out of
the 9 miRNAs (miR-221, miR-744, miR-376c, miR-191, miR-
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elevated levels in GC group with more than 2-fold change
(P,0.05), and these miRNAs were selected for the following
analyses.
Risk assessment of GC cases using a panel of miRNAs
To evaluate the discriminating effect of serum miRNAs on GC,
ROC curves were established for each of the 8 miRNAs using 68
pairs of GC and control in the second-stage validation (Figure 3).
The results revealed that miR-744, miR-376c, miR-221 and let-7e
yielded the largest areas under the ROC curves (AUCs) and might
have the potential as biomarkers for GC detection.
Risk assessment based on the four miRNAs was used to
distinguish serum samples of GC cases from controls. For each
miRNA, we firstly calculated the optimal cut-off value of the
relative expression level (miR-744: 5.49610
24; miR-376c:
6.05610
24; miR-221: 1.47610
23; let-7e: 1.61610
23), at which
the Youden’s index (sensitivity+specificity-1) for GC diagnosis was
largest at the ROC curve. Then we divided the subject into a high-
risk group, representing the possible GC case, when the serum
level of any of the four miRNAs was equal or greater than the
corresponding cut-off value, and a low-risk group, representing the
control, when the serum levels of all the four miRNAs were less
than the cut-off values.
According to this assessment criterion, 56 GCs and 32 controls
were correctly predicted as GC and non-GC cases, producing the
sensitivity of 82.4% and the specificity of 47.1%. Since let-7e
demonstrated the smallest value and widest confidence interval of
AUC among the four miRNAs in the ROC curve analysis
(Figure 3), we repeated the above risk assessment after excluding
let-7e and obtained a higher specificity (40/68, 58.8%) while the
sensitivity remained unchanged, indicating that the contribution of
let-7e to differentiating GCs from controls was negligible, and the
three-miRNA panel (miR-221, miR-376c and miR-744) was a
more efficient combination of biomarkers for GC diagnosis.
To further examine the potential of this panel for early
detection of GC, we assessed a subgroup of 30 GC patients in
early stage, and 22 were correctly predicted as GC cases with the
sensitivity of 73.3%.
Association between serum miRNA expression and
differentiation grades of GC
Furthermore, we sought to investigate the correlation between
expression levels of miR-221, miR-744 and miR-376c, and
differentiation grades of GC. As shown in Figure 4A–C, all the
three miRNAs showed higher serum levels in poorly differentiated
GC group (43 GCs including 29 male and 14 female; age, 60 (SD
8.3) years) than in well or moderately differentiated GC group (24
GCs including 19 male and 5 female; age, 60 (SD 6.2) years).
Among them, serum miR-221 and miR-376c demonstrated
significantly positive correlation with poor differentiation of GC
(P=0.006 and 0.004, respectively).
Expression levels of serum miRNA biomarkers in subjects
with DYS
To further elucidate the relevance of these three miRNAs with
premalignant gastric lesion, we examined their expressions in 46
pairs of DYS and control. As shown in Figure 4D–F, a significantly
elevated level of miR-221 was found in DYS group when
compared to controls (P=0.027), while no significant difference
was found for miR-376c or miR-744. Further risk assessment
analysis following previously established procedures revealed that
this three-miRNA panel could distinguish DYS from control with
the sensitivity of 56.5% and the specificity of 47.8%.
Dynamic changes of serum miRNA biomarkers during GC
development
In the retrospective study, the dynamic changes of the three
serum miRNA biomarkers were detected on 58 GC patients who
were divided into four groups according to the time interval from
blood draw to GC diagnosis: pre-diagnosis 2–5-year, 6–9-year,
10–14-year and $15-year groups (Table 2). Some subjects may
simultaneously exist in two or more than two groups since they
provided serum samples in multiple time points of the follow-up
period.
As shown in Figure 5A, all three serum miRNAs displayed
markedly increasing expression during GC development, except
slight increase of serum miR-744 in the pre-diagnosis $15-year
group. Further trend test showed a statistically significant linear
trend in the three miRNA levels among 20 GC patients who
contributed three serum samples at different time points during
the follow-up period (Figure 5B).
Finally, we evaluated the potential of miRNA biomarkers for
early prediction of GC in 29 patients, who had provided serum
samples at 2–5 years before GC diagnosis. According to the risk
assessment criterion established before, 23 of the 29 GC patients
(79.3%) were correctly classified as the represented GC cases by
this three-serum miRNA panel.
Table 1. Subject information of the case-control study.
Variables
GC
n=82
Control
n=82
DYS
n=46
Control
n=46
Age (year, Mean 6 SD) 60.467.5 60.367.5 58.3610.4 58.1610.0
Gender (%)
Male 58 (70.7) 58 (70.7) 39 (84.8) 39 (84.8)
Female 24 (29.3) 24 (29.3) 7 (15.2) 7 (15.2)
Lauren’s types (%)
Intestinal 32 (39.0)
Diffuse 6 (7.3)
Mixed 1 (1.2)
Uncertain 1 (1.2)
Missing 42 (51.3)
Histology (%)
Adenocarcinoma 71 (86.6)
Signet ring cell 3 (3.7)
Squamous carcinoma 1 (1.2)
Missing 7 (8.5)
Differentiation (%)
Well 5 (6.1)
Moderately 19 (23.2)
Poorly 43 (52.4)
Missing 15 (18.3)
Metastasis (%)
Yes 22 (26.8)
No 31 (37.8)
Missing 29 (35.4)
doi:10.1371/journal.pone.0033608.t001
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The aim of this study was to identify differential miRNAs in the
serum of GC and DYS, and investigate the potential of serum
miRNAs as biomarker for early detection of GC. We found the
significantly elevated levels of serum miR-221, miR-376c and
miR-744 in GC patients through systematic microarray-based
screening and two-stage validation. This three-serum miRNA
panel could distinguish GCs from controls and showed an
increasing trend during GC development. To the best of our
knowledge, this is the first population-based study in exploring the
dynamic changes of serum miRNAs associated with GC and its
precursors in a high-risk area of GC.
The incidence of GC varies widely throughout the world with
the highest rates occurring in eastern Asia, including Japan, Korea
and China [1,2]. In China, most of GCs are diagnosed at
advanced stages resulting in poor prognosis with an average 5-year
survival rate ,30%, while in Japan and Korea over 60% of GCs
are diagnosed at early stage by community-based endoscopic
screening with 5-year survival rate .80% [29,30]. Although the
impact of early detection of GC by endoscopic screening is
significant in Linqu, there has been only a few population-based
screening for GC in China due to high cost and lack of skilled
endoscopists.
GC is an end result of multi-stage gastric lesions with different
biological features, which provides an opportunity to detect GC in
early stage by using biomarkers. In our previous study, we found
the ratio of serum PG I/II monotonically declined with the
severity of gastric lesions, however, the sensitivity and specificity
for predicting advanced gastric lesions and GC were poor [31].
Recently, accumulating evidence indicated that miRNAs play
important roles in oncogenesis, and tumor-derived miRNAs can
enter the circulation in a remarkably stable form [11,32,33],
suggesting that miRNAs could be used as novel non-invasive
biomarkers for early detection of GC.
More recently, a study identified four upregulated GC-
associated miRNAs (miR-17-5p, miR-21, miR-106a and miR-
106b) [34], which also displayed higher expression levels in GC
serum on our array, whereas the striking downregulation of let-7a
in their study was not observed by us. Another study found five
elevated serum miRNAs (miR-1, miR-20a, miR-27a, miR-34 and
miR-423-5p) in GC patients [13], whereas only miR-20a and
miR-27a were upregulated on our array, and miR-27a was
validated to be remarkably overexpressed in GC patients. The
Figure 2. Serum levels of the selected miRNAs in 68 pairs of GC and control subjects in the second-stage validation. The median fold
changes of miRNA levels comparing GC with control were given and the Wilcoxon tests were performed to examine the difference between two
groups. The relative levels of miRNAs (log10 scale at Y-axis) were normalized to the spiked-in cel-miR-39.
doi:10.1371/journal.pone.0033608.g002
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controls. Serum (A) miR-744, (B) miR-376c, (C) miR-221 and (D) let-7e yielded the largest areas under the ROC curves (AUCs).
doi:10.1371/journal.pone.0033608.g003
Figure 4. Association of the selected serum miRNA levels with GC differentiation grades and DYS. (A–C) Box plots of serum miR-221,
miR-376c and miR-744 levels in 24 well or moderately differentiated and 43 poorly differentiated GC patients. (D–F) Box plots of serum miR-221, miR-
376c and miR-744 levels in 46 DYS subjects and matched controls. The Mann-Whitney U tests (A–C) and the Wilcoxon tests (D–F) were performed to
examine the difference between two groups, respectively. The relative levels of miRNAs (log10 scale at Y-axis) were normalized to the spiked-in cel-
miR-39 (A–F).
doi:10.1371/journal.pone.0033608.g004
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types, screening tools or quantification methods [35].
Among the three serum miRNAs identified in our study, miR-
221 has been found abnormally upregulated in tissues of many
cancer types, such as gastric [24], colorectal [21], prostate [36]
and breast cancer [37]. MiR-221 could post-transcriptionally
suppress p27 and p57, thus facilitating G1/S phase transition and
enhancing cell proliferation and tumor growth [24,36,38,39].
Studies have shown that the expression level of miR-221 in plasma
was associated with overall survival of colorectal cancer [40] and
the progression of prostate cancer [41]. Only a few studies have
explored the functional relevance of miR-376c, such as miR-376c
could enhance proliferation, survival and chemoresistance of
ovarian cancer cell by targeting ALK7 [42]. For miR-744, its
expression pattern, physiological function and relationship with
carcinogenesis are unknown at present.
In our current study, we found this three-miRNA panel could
distinguish serum samples of GC from controls with a sensitivity of
82.4% and specificity of 58.8%. In addition, our study indicated
that among 30 early-stage GC patients, 22 (73.3%) were correctly
classified, suggesting this panel might serve as a biomarker for
early detection of GC. It also raises the possibility that this panel of
miRNAs may be useful as a preliminary screening method for GC
in general population at high risk of GC.
We were also interested in exploring the associations between
these three serum miRNAs and differentiation grades of GC. By
comparing miRNA levels in serum of GC patients with various
grades, we found a higher serum miRNA expression in poorly
differentiated GC. This result revealed that high expression level
of these serum miRNAs in GC patients was associated with the
advanced stage of GC. Although the mechanism of this
phenomenon is unclear, the high level of these miRNAs in serum
may have some value for indicating the progression and treatment
selection of GC.
We further assessed whether this three-miRNA panel could
predict advanced gastric lesions, such as DYS. We found only
miR-221 displayed an elevated expression level in DYS, suggesting
this panel was more specific for GC. Despite the limited effect of
this panel on DYS detection, miR-221, one of the three serum
miRNAs, may be useful for identifying those DYS subjects at the
extremely high risk of developing GC. Interestingly, by prospec-
tively tracking the evolution of these DYS subjects, we found the
lower rate of regression to the less severe lesions and one incident
GC in the predicted high-risk group who had higher level of serum
miR-221 (data not shown).
By retrospectively examining the expression of three serum
miRNAs in pre-diagnosis samples of GC patients, we found an
increasing trend during GC development, and further analysis
indicated that this panel could predict GC up to 5 years ahead of
clinical GC diagnosis. These results strongly supported the value of
these three miRNAs for predicting GC occurrence. Combining
this three-serum miRNA signature with pathological diagnosis
may enhance early detection of GC in subjects with advanced
gastric lesions, such as IM and DYS.
To rule out the possibility that increased age and shorter storage
period of serum samples contributed to higher level of miRNAs
over time, we analysed miRNA expression in 82 controls who
underwent blood draw at the same time points with GC patients.
No significant difference was observed during the follow-up period
(data not shown), suggesting that the rising serum miRNA levels
throughout GC development could not be attributed to increased
age and supporting that miRNAs were present in serum in a stable
form. Accordingly, circulating miRNAs might be used as a
biomarker to develop a non-invasive test for GC detection in the
future because of its easy accessibility, high stability and low assay
cost.
Our study has several strengths. Firstly, all subjects came from a
high-risk population of GC and underwent rigorous pathologic
diagnosis, which justified our hypothesis that the observed
difference in serum miRNA levels between GCs and controls
could be attributed mostly, if not all, to the neoplastic
transformation. Secondly, our population-based study with a high
compliance and more than 20 years’ follow-up enhanced the
reliability of the study, and provided the first evidence on dynamic
changes of serum miRNAs during GC development as well as
their potential as biomarkers to identify high-risk individuals of
GC.
This study also has some limitations. Because very few subjects
were diagnosed with normal gastric mucosa in this population
[17], we used subjects with SG/mild CAG as controls. However,
compared to studies using generally normal subjects as control,
our pathologic diagnosis-based control selection strategy diluted
the disparity between cases and controls, and thus could only cause
the underestimation of results. In addition, the findings of this
preliminary study with small sample size necessitate further
confirmation in large prospective studies and the functional
Table 2. Information of the 58 GC cases for the retrospective study.
Variables
Pre-diagnosis $15-year
group n=12
Pre-diagnosis 10–14-year
group n=36
Pre-diagnosis 6–9-year
group n=27
Pre-diagnosis 2–5-year
group n=29
Age (year, Mean 6 SD) 54.364.9 55.2610.3 58.069.6 60.268.4
Gender (%)
Male 5 (41.7) 25 (69.4) 20 (74.1) 20 (69.0)
Female 7 (58.3) 11 (30.6) 7 (25.9) 9 (31.0)
Pathologic diagnosis (%)
Superficial gastritis - - 3 (11.1) -
Chronic atrophic gastritis 1 (8.3) 4 (11.1) 2 (7.4) -
Intestinal metaplasia 4 (33.3) 19 (52.8) 9 (33.3) 10 (34.5)
Dysplasia 5 (41.7) 12 (33.3) 12 (44.4) 19 (65.5)
Missing 2 (16.7) 1 (2.8) 1 (3.8) -
doi:10.1371/journal.pone.0033608.t002
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clarified.
In conclusion, through this population-based study we identified
a set of differential serum miRNAs (miR-221, miR-376c and miR-
744) in GC and proposed their potential as novel non-invasive
biomarkers for early detection of GC.
Supporting Information
Figure S1 Serum levels of the 16 selected miRNAs in 14
pairs of GC and control subjects in the first-stage
validation. The median fold changes of miRNA levels
comparing GC with control were given and the Wilcoxon tests
Figure 5. The temporal trends of serum miR-221, miR-376c and miR-744 levels during GC development. (A) In the retrospective study,
miRNA levels were examined in the pre-diagnosis serum samples of 58 cases that were classified into four groups according to the time interval
between blood collection and GC diagnosis. (B) The trend tests of miRNA levels over time were performed in 20 GC cases who provided three serum
samples at three time points of the follow-up (in the years of 1989, 1992 and 1999; or in the years of 1989, 1994 and 2003). The mean values of
relative miRNA levels that were normalized to the spiked-in cel-miR-39 and transformed on a logarithmic scale were shown with the error bar
representing 95% CI (A–B).
doi:10.1371/journal.pone.0033608.g005
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The relative levels of miRNAs (log10 scale at Y-axis) were
normalized to the spiked-in cel-miR-39.
(JPG)
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